Antisense oligonucleotides are short synthetic strands of nucleic acid chemicals that bind to target messenger RNA (mRNA) in a sequence-specific manner in order to control gene expression by inhibiting translation or causing degradation of that mRNA.
Antisense oligonucleotides are used to treat a variety of rare genetic diseases and have advantages over conventional small molecule drugs as they can directly interfere with disease-causing genes. Ionis Pharmaceuticals, Biogen and Alnylam Pharmaceuticals are expanding the clinical pipeline for antisense drugs targeting neurological diseases like spinal muscular atrophy (SMA) and Huntington's disease. The versatility and efficacy of these precision medicines in treating previously untreatable conditions is driving their adoption in specialty therapeutics.
The Global Antisense Oligonucleotides Market is estimated to be valued at US$ 5.8 billion in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024-2031.
Key Takeaways
Key players: Key players operating in the Antisense Oligonucleotides Market Size are Ionis Pharmaceuticals, Biogen, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals and Janssen Global Services.
Growing demand: Increasing prevalence of rare genetic disorders and growing patients suffering from neurodegenerative disorders are fueling the demand for antisense oligonucleotide drugs. These drugs provide superior treatment outcomes for conditions with high unmet needs.
Technological advancement: Continuous efforts to improve the pharmacokinetic properties and optimize delivery of these drugs have resulted in second-generation antisense therapies with improved safety and efficacy profiles. Novel backbone chemistries and conjugate delivery technologies are enhancing clinical translation.
Market Trends
Target expansion: Antisense oligonucleotide players are evaluating new disease targets beyond neurological disorders. Oncology is emerging as a key therapeutic area utilizing RNA targeting capabilities of these drugs.
Combination therapies: Combining antisense oligonucleotides with other complementary drugs can potentially result in enhanced treatment effects. Partnerships to evaluate combination regimens will be important for targeting multiple disease pathways.
Market Opportunities
Neurological disorders: Large neurological disease markets like Alzheimer's represent major commercial opportunities. Drugs demonstrating efficacy in conditions like SMA have set the precedent.
Rare diseases: Orphan drug designation provides lucrative market exclusivity despite small patient pools. Development of first-in-class treatments for rare genetic disorders poses major market potential.
The COVID-19 pandemic has significantly impacted the growth of the antisense oligonucleotides market. During the initial outbreak and lockdowns across regions, supply chains were disrupted leading to shortages of raw materials required for manufacturing antisense oligonucleotides. Restrictions on non-essential medical procedures and people avoiding hospitals also decreased the demand for therapies utilizing antisense oligonucleotides in indications like neurological disorders and cardiovascular diseases.
However, as the pandemic spread further, focus shifted to developing treatments against COVID-19 using Antisense Oligonucleotides Market Regional Analysis. Several pharmaceutical companies launched clinical trials to evaluate antisense oligonucleotides targeting the genes essential for SARS-CoV-2 virus replication. Positive results from such trials can potentially lead to the approval of the first antisense oligonucleotide drug against COVID-19. This has reignited investments in antisense oligonucleotide research and accelerated pipeline development activities.
As vaccination drives progress globally, non-COVID healthcare has resumed gradually. This has boosted the demand for pre-existing antisense oligonucleotide drugs. At the same time, experiences from COVID-19 response like expanded use of telemedicine and decentralized clinical trials are expected to further fuel the market growth in the coming years. Overall, while short-term growth was hampered due to COVID-19 disruptions, the pandemic has opened newer long-term opportunities for antisense oligonucleotides development.
Get more insights on- Antisense Oligonucleotides Market
Explore More Related Article On- Tuberculosis Vaccine
For Deeper Insights, Find the Report in the Language that You want
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)